+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Amyotrophic Lateral Sclerosis Market: By Drug Type By Treatment Type By Distribution Partners & Geography - Forecast 2016-2021

  • ID: 3820797
  • Report
  • 138 pages
  • IndustryARC
1 of 2
Amyotrophic lateral sclerosis (ALS) is a neurological disease and also termed as Lou Gehrig’s disease which results in a specific disorder that involves the death of neurons that control voluntary muscles. This is a fast progressing, invariably fatal neurological disease that attacks and damages the nerve cells (neurons) which responsible for controlling voluntary muscles. This disease is classified amongst group of disorders known as motor neuron diseases which involves gradual degeneration and death of motor neurons located in the brain, brain stem, and spinal cord. Motor Neurons acts as controlling units and vital communication links between the nervous system and the voluntary muscles of the body. Initial symptoms of this disease include fasciculation, cramps, tight and stiff muscles, muscle weakness affecting an arm or a leg, slurred and nasal speech, or difficulty chewing or swallowing which are generally overlooked or ignored.

This report identifies the global Amyotrophic lateral sclerosis market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to global Amyotrophic lateral sclerosis market.

Globally North America contributed highest revenues in Amyotrophic lateral sclerosis market due high number of reported instances and deep reach of the treatments to the large number of population followed by Europe and Asia-Pacific regions as the second and third largest markets for Amyotrophic lateral sclerosis. Developing medical infrastructure in the emerging economies is expected to drive the growth of Amyotrophic lateral sclerosis market in these economies in the near future.

In these report global Amyotrophic lateral sclerosis market is further segmented based on the basis of drug type, treatment type and distribution channel partners and geography type as follows:

Global Amyotrophic Lateral Sclerosis Market, By Drug Type (2014-2021): Riluzole, and Nuedexta
Global Amyotrophic Lateral Sclerosis Market, By Treatment Type (2014-2021): Stem Cell Therapy, and Chemotherapy
Global Amyotrophic Lateral Sclerosis Market, By Distribution Partners(2014-2021): Hospitals, Diagnostic centres, Clinics, and Retail Pharmacies
This is report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the global Amyotrophic lateral sclerosis market. Some of the major companies’ profiles in detail are as follows:

GNT Pharma
Synthetic Biologics
Avicena inc
Amkor Pharma
Mitsubishi Tanabe Pharma
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 2
1. Amyotrophic Lateral Sclerosis – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Amyotrophic Lateral Sclerosis – Market Forces
4.1. Drivers
4.1.1. Globally increasing incidences of anaplastic astrocytoma
4.2. Restraints
4.2.1. Low awareness and R&D activities in developing countries
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Amyotrophic Lateral Sclerosis Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Global Amyotrophic Lateral Sclerosis Market, By Drug Type (2014-2021)
6.1. Riluzole
6.2. Nuedexta

7. Global Amyotrophic Lateral Sclerosis Market, By Treatment Type (2014-2021)
7.1. Stem Cell Therapy
7.2. Chemotherapy

8. Global Amyotrophic Lateral Sclerosis Market, By Distribution Partners(2014-2021)
8.1. Hospitals
8.2. Diagnostic centres
8.3. Clinics
8.4. Retail Pharmacies

9. Global Amyotrophic Lateral Sclerosis Market, By Geography (2014-2021)
9.1. Europe
9.1.1. Germany
9.1.2. France
9.1.3. Italy
9.1.4. Spain
9.1.5. Russia
9.1.6. U.K.
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.1. China
9.2.2. India
9.2.3. Japan
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.3.3. Mexico
9.4. Rest of the World (RoW)
9.4.1. Brazil
9.4.2. Rest of RoW

10. Amyotrophic Lateral Sclerosis – Market Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (Top 10 Companies)
11.1. GNT Pharma
11.1.1. Introduction
11.1.2. Financials
11.1.3. Key Insights
11.1.4. Key Strategy
11.1.5. Product Portfolio
11.1.6. SWOT Analysis
11.2. Synthetic Biologics
11.2.1. Introduction
11.2.2. Financials
11.2.3. Key Insights
11.2.4. Key Strategy
11.2.5. Product Portfolio
11.2.6. SWOT Analysis
11.3. Avicena inc
11.3.1. Introduction
11.3.2. Financials
11.3.3. Key Insights
11.3.4. Key Strategy
11.3.5. Product Portfolio
11.3.6. SWOT Analysis
11.4. Amkor Pharma
11.4.1. Introduction
11.4.2. Financials
11.4.3. Key Insights
11.4.4. Key Strategy
11.4.5. Product Portfolio
11.4.6. SWOT Analysis
11.5. Mitsubishi Tanabe Pharma
11.5.1. Introduction
11.5.2. Financials
11.5.3. Key Insights
11.5.4. Key Strategy
11.5.5. Product Portfolio
11.5.6. SWOT Analysis
11.6. Sanofi
11.6.1. Introduction
11.6.2. Financials
11.6.3. Key Insights
11.6.4. Key Strategy
11.6.5. Product Portfolio
11.6.6. SWOT Analysis
11.7. Biogen Inc.
11.7.1. Introduction
11.7.2. Financials
11.7.3. Key Insights
11.7.4. Key Strategy
11.7.5. Product Portfolio
11.7.6. SWOT Analysis
11.8. Apotex Corp
11.8.1. Introduction
11.8.2. Financials
11.8.3. Key Insights
11.8.4. Key Strategy
11.8.5. Product Portfolio
11.8.6. SWOT Analysis
11.9. Mylan Pharmaceuticals Inc
11.9.1. Introduction
11.9.2. Financials
11.9.3. Key Insights
11.9.4. Key Strategy
11.9.5. Product Portfolio
11.9.6. SWOT Analysis
11.10. Impax Laboratories
11.10.1. Introduction
11.10.2. Financials
11.10.3. Key Insights
11.10.4. Key Strategy
11.10.5. Product Portfolio
11.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 2